Registration Opens for MDA Summer Camp for Children with Neuromuscular Diseases
January 17, 2023 09:00 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 17, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for its MDA Summer Camp program for children ages 8 to 17 living...
FDA’s Peter Marks, M.D., Ph.D. to deliver Keynote Address at 2023 Muscular Dystrophy Association Clinical & Scientific Conference
January 10, 2023 06:00 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced Peter Marks, M.D., Ph.D. as the Keynote Speaker at the MDA 2023 Clinical & Scientific...
Muscular Dystrophy Association Elects Governor Brad Henry as Chairman and Christopher Rosa, Ph.D. as Vice Chairman of the Board of Directors
January 09, 2023 09:20 ET
|
Muscular Dystrophy Association
New York, NY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the election of new Board of Directors leadership. Governor Brad Henry will now serve as...
Duchenne Muscular Dystrophy Market to Hit Sales of $1533.72 Million by 2028 | DMD Affects 250,000 Children Each Year | Gene Therapy is the Only effective Way to Treat DMD
September 28, 2022 10:22 ET
|
SkyQuest Technology Consulting Pvt. Ltd.
Westford,USA, Sept. 28, 2022 (GLOBE NEWSWIRE) -- There is an increasing demand for Duchenne muscular dystrophy (DMD) therapies, as the condition is still not curable. In the medical industry, there...
miRecule Inc. closes $5.7 M to Create Breakthrough RNA Therapies for Cancer and Muscular Dystrophy
May 27, 2021 11:07 ET
|
miRecule
GAITHERSBURG, Md., May 27, 2021 (GLOBE NEWSWIRE) -- miRecule, Inc. (“miRecule”), an emerging biotech company focused on the development of cutting-edge RNA therapeutics, announced today it has...
AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical Trials
January 29, 2020 10:27 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, today introduced...
Going the Distance for Duchenne
July 09, 2019 15:34 ET
|
Jett Foundation
Plymouth, MA, July 09, 2019 (GLOBE NEWSWIRE) -- A group of inspiring young people will join Jett Foundation, a non-profit organization dedicated to awareness and helping fight Duchenne muscular...
MDA Awards $300,000 to Streamline Gathering of Data for ALS Research
June 15, 2017 16:24 ET
|
Muscular Dystrophy Association
Chicago, June 15, 2017 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association has announced the award of a clinical research network grant (CRNG) to Michael Benatar, M.D., Ph.D., at the University...
Gala Global to Finalize Initial Hemp "CBD" Products
February 11, 2015 08:00 ET
|
Gala Pharmaceutical Inc.
LOS ANGELES, Feb. 11, 2015 (GLOBE NEWSWIRE) -- Gala Global, Inc. (OTCQB:GLAG) today announced it has finalized the initial CBD products. The initial products will based on flavored infused CBD Oral...
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
September 08, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...